J
Jérôme Durivault
Researcher at University of Nice Sophia Antipolis
Publications - 32
Citations - 1204
Jérôme Durivault is an academic researcher from University of Nice Sophia Antipolis. The author has contributed to research in topics: Vascular endothelial growth factor & Warburg effect. The author has an hindex of 14, co-authored 27 publications receiving 841 citations. Previous affiliations of Jérôme Durivault include French Institute of Health and Medical Research.
Papers
More filters
Journal ArticleDOI
The HIF-1–Inducible Lysyl Oxidase Activates HIF-1 via the Akt Pathway in a Positive Regulation Loop and Synergizes with HIF-1 in Promoting Tumor Cell Growth
Floriane Pez,Frédéric Dayan,Jérôme Durivault,Bastien Kaniewski,Géraldine Aimond,Gabrielle S. Le Provost,Blandine Deux,Philippe Clézardin,Pascal Sommer,Jacques Pouysségur,Caroline Reynaud +10 more
TL;DR: Mechanistic investigations revealed that LOX activated the PI3K (phosphoinositide 3-kinase)-Akt signaling pathway, thereby upregulating HIF-1α protein synthesis in a manner requiring LOX-mediated hydrogen peroxide production, suggesting that Hif-1/LOX mutual regulation is a pivotal mechanism in the adaptation of tumor cells to hypoxia.
Journal ArticleDOI
Genetic Disruption of the Multifunctional CD98/LAT1 Complex Demonstrates the Key Role of Essential Amino Acid Transport in the Control of mTORC1 and Tumor Growth
Yann Cormerais,Sandy Giuliano,Renaud Lefloch,Benoît Front,Jérôme Durivault,Eric Tambutté,Pierre-André Massard,Laura R. de la Ballina,Hitoshi Endou,Michael F. Wempe,Manuel Palacín,Scott K. Parks,Jacques Pouysségur +12 more
TL;DR: It is established that LAT1 transport activity is the key growth-limiting step of the heterodimer and advocate the pharmacology development of LAT1 transporter inhibitors as a very promising anticancer target.
Journal ArticleDOI
Genetic ablation of the cystine transporter xCT in PDAC cells inhibits mTORC1, growth, survival and tumor formation via nutrient and oxidative stresses
Boutaina Daher,Scott K. Parks,Jérôme Durivault,Yann Cormerais,Hanane Baidarjad,Eric Tambutté,Jacques Pouysségur,Milica Vučetić +7 more
TL;DR: In vitro pharmacological inhibition of xCT by low concentrations of erastin phenocopied xCT-KO and potentiated the cytotoxic effects of both gemcitabine and cisplatin in PDAC cell lines strongly support that inhibition ofxCT, by its dual induction of nutritional and oxidative cellular stresses, has great potential as an anticancer strategy.
Journal ArticleDOI
Double genetic disruption of lactate dehydrogenases A and B is required to ablate the "Warburg effect" restricting tumor growth to oxidative metabolism.
Maša Ždralević,Almut Brand,Lorenza Di Ianni,Katja Dettmer,Jörg Reinders,Katrin Singer,K. Peter,Annette Schnell,Christina Bruss,Sonja-Maria Decking,Gudrun E. Koehl,Blanca Felipe-Abrio,Jérôme Durivault,Pascale Bayer,Marie Evangelista,Thomas O'Brien,Peter J. Oefner,Kathrin Renner,Jacques Pouysségur,Marina Kreutz,Marina Kreutz +20 more
TL;DR: It is demonstrated that the Warburg effect is not only based on high LDHA expression, as both LDHA and LDHB need to be deleted to suppress fermentative glycolysis, and that the metabolic shift to OXPHOS caused by LDHA/B genetic disruptions is responsible for the tumors' escape and growth.
Journal ArticleDOI
The glutamine transporter ASCT2 (SLC1A5) promotes tumor growth independently of the amino acid transporter LAT1 (SLC7A5)
Yann Cormerais,Pierre André Massard,Milica Vučetić,Sandy Giuliano,Eric Tambutté,Jérôme Durivault,Valérie Vial,Hitoshi Endou,Michael F. Wempe,Scott K. Parks,Jacques Pouysségur +10 more
TL;DR: ASCT2KO reduces tumor growth by limiting AA import, but that this effect is independent of LAT1 activity, which indicates that the proposed functional coupling model of ASCT2 and LAT1 is not universal across different cancer types.